Proceedings of the National Academy of Sciences · 2021 · 47 citations · 43 references
Life SciencesMicrobiologyPharmacologyDrug DesignDrug DiscoveryProtein EngineeringAntibacterial PharmacologyAntibiotic ResistanceBacterial BiofilmsBiofilm Formation In InfectionBiofilm-associated ResistanceMicrobial BiofilmsAnti-biofilm StrategiesBiofilm ControlBiofilm Control StrategiesBiofilm Drug ToleranceBiofilm InhibitionBiofilm-disrupting AgentsChemical Inhibition Of BiofilmsPurification Yields
Significance Pseudomonas aeruginosa is a major cause of hospital-acquired infections due to its formation of biofilms that are highly tolerant to antibiotics. Conventional drugs often fail to kill slowly growing biofilms because they do not target the mechanisms that sustain cells in this state; alternative biofilm control strategies are thus urgently needed. One way in which P. aeruginosa builds robust biofilms is through the production of redox-active phenazines such as pyocyanin. We identified an enzyme that degrades pyocyanin but were stymied in studying its potential to combat biofilms due to its poor expression yield. Here we show how protein design can stabilize the enzyme to improve purification yields, enabling physiological studies to reveal a novel enzyme’s therapeutic potential.
43
Microtiter Dish Biofilm Formation Assay
George A. O’Toole · Journal of Visualized Experiments · 2011 · 2.2K citations · Full text
Marshall Charles Walters, Frank Roe, Amandine Bugnicourt et al. · Antimicrobial Agents and Chemotherapy · 2002 · 966 citations · Full text